within Pharmacolibrary.Drugs.ATC.R;

model R03BA03
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 2.1666666666666667e-05,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.002,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>R03BA03</td></tr><td>route:</td><td>inhalation</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Flunisolide is a synthetic corticosteroid with anti-inflammatory properties, commonly used as an inhaled medication for the prophylactic and symptomatic treatment of asthma. It is administered via inhalation route and is approved for use in many countries as an asthma controller medication.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated based on typical information available for inhaled corticosteroids, as no direct population PK study with compartment modeling and full PK parameters for inhaled flunisolide in humans could be identified in the public literature.</p><h4>References</h4><ol><li><p>Richards, J, et al., &amp; Newman, SP (2001). Deposition and pharmacokinetics of flunisolide delivered from pressurized inhalers containing non-CFC and CFC propellants. <i>Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine</i> 14(2) 197–208. DOI:<a href=&quot;https://doi.org/10.1089/08942680152484126&quot;>10.1089/08942680152484126</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11681651/&quot;>https://pubmed.ncbi.nlm.nih.gov/11681651</a></p></li><li><p>Dickens, GR, et al., &amp; Choudhury, S (2000). Pharmacokinetics of flunisolide administered via metered dose inhaler with and without a spacer device and following oral administration. <i>Annals of allergy, asthma &amp; immunology : official publication of the American College of Allergy, Asthma, &amp; Immunology</i> 84(5) 528–532. DOI:<a href=&quot;https://doi.org/10.1016/S1081-1206(10)62517-3&quot;>10.1016/S1081-1206(10)62517-3</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/10831007/&quot;>https://pubmed.ncbi.nlm.nih.gov/10831007</a></p></li><li><p>Melani, AS (2014). Flunisolide for the treatment of asthma. <i>Expert review of clinical pharmacology</i> 7(3) 251–258. DOI:<a href=&quot;https://doi.org/10.1586/17512433.2014.908117&quot;>10.1586/17512433.2014.908117</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24716719/&quot;>https://pubmed.ncbi.nlm.nih.gov/24716719</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end R03BA03;
